Status and phase
Conditions
Treatments
About
This study will evaluate the efficacy and safety of RC48-ADC combined with AK104 in HER2-expression locally advanced or metastatic urothelial carcinoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
36 participants in 1 patient group
Loading...
Central trial contact
Wang Xin Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal